Autopsy report · NCT03358407

GSK2983559 First Time in Human Study

“Terminated due to non clinical toxicology findings and reduced safety margins.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 1 month before it stopped.
• 31 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Inflammatory Bowel Diseases

Interventions

GSK2983559; Placebo

Participants

31

Sites

1

Countries

United Kingdom

Trials that died the same way

• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (83% match in meaning)
• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (76% match in meaning)
• A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
  “This study was terminated due to lack of clinical activity and not due to safety reasons.” (75% match in meaning)
• QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
  “Prematurely terminated due to lack of therapeutic effect” (74% match in meaning)
• A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
  “Terminated due to dose limiting toxicity” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.